Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling Partial and Total Support of Left Ventricular Assist Device for Discrete Hemodynamic Control Framework.

IEEE transactions on bio-medical engineering·2026
Same author

Renal Hemodynamic and Urinary Response to Baroreflex-Mediated Sympathetic Modulation: Insights from High-Resolution Arterial Impedance Analysis in Rats.

American journal of physiology. Regulatory, integrative and comparative physiology·2026
Same author

Positive End-expiratory Pressure Is Associated With Apparent Increases in Single-beat Left-ventricular End-systolic Elastance: Implications of Stroke Volume Sensitivity.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Self-folding graphene scaffolds with integrated electronics for cardiac tissue engineering.

Nanoscale·2026
Same author

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten.

JACC. Case reports·2026
Same author

Automated hemodynamic management system for the prevention of hypotension and cardiac output reduction during general anesthesia: preclinical experimental validation.

Journal of anesthesia·2026

Related Experiment Video

Updated: Jan 14, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

A Discrete Hemodynamic Control Framework: Proof-of-Concept Study for Autonomous Drug Therapy in Acute Heart Failure.

Yasuyuki Kataoka, Kazunori Uemura, Mitsuji Sampei

    IEEE Transactions on Bio-Medical Engineering
    |January 12, 2026
    PubMed
    Summary

    This study developed an autonomous drug therapy system for acute heart failure (AHF) that stabilizes hemodynamics and reduces myocardial oxygen consumption. The framework enhances treatment precision and supports clinical decision-making in critical care settings.

    More Related Videos

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.8K
    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
    12:43

    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

    Published on: August 16, 2016

    20.9K

    Related Experiment Videos

    Last Updated: Jan 14, 2026

    Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
    07:49

    Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

    Published on: July 21, 2023

    1.9K
    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.8K
    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
    12:43

    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

    Published on: August 16, 2016

    20.9K

    Area of Science:

    • Cardiovascular Physiology
    • Critical Care Medicine
    • Control Systems Engineering

    Background:

    • Managing acute heart failure (AHF) presents challenges in stabilizing hemodynamics while minimizing myocardial oxygen consumption.
    • Complex cardiovascular interactions necessitate advanced therapeutic strategies for optimal patient outcomes.

    Purpose of the Study:

    • To develop a discrete hemodynamic control framework for autonomous drug therapy in AHF.
    • To enhance control versatility and clinical potential in managing AHF.
    • To optimize hemodynamic targets and minimize myocardial oxygen consumption.

    Main Methods:

    • Derived a multi-input, multi-output model of cardiovascular dynamics and drug responses.
    • Designed an optimal control framework for regulating hemodynamic targets and drug administration.
    • Incorporated clinical constraints, including dosage limits and contraindications.
    • Validated control performance using a cardiovascular simulator.

    Main Results:

    • Achieved multi-dimensional hemodynamic regulation and reduced myocardial oxygen consumption in simulated AHF scenarios.
    • Successfully identified pharmacologically untreatable cases by assessing the reachable hemodynamic range.
    • Demonstrated stable performance despite inter-patient variability in drug sensitivities and circulatory properties.

    Conclusions:

    • The developed system can serve as a physician-assistive tool for acute heart failure management.
    • It provides a foundation for autonomous drug therapy, improving treatment precision and reducing clinician burden.
    • Offers a scalable approach to advance critical care and optimize drug therapy in AHF.